Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
NCT02174432
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Prurigo Nodularis
Nodularis Prurigo
Prurigo
Interventions
DRUG:
nalbuphine HCl ER
Sponsor
Trevi Therapeutics